The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2024 | Novel targets for CAR-T therapy in MCL
In this video, Mike Barnkob, MD, PhD, Odense University Hospital, Odense, Denmark, explores the use of mass spectrometry to identify novel antigen targets for CAR T-cell therapy in mantle cell lymphoma (MCL). Dr Barnkob expresses optimism regarding the possibility of targeting multiple antigens to improve the longevity of treatment responses. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy fees: Kite/Gilead, Roche
